การรักษามะเร็งเม็ดเลือดขาว
Keywords:
-Abstract
-
Downloads
References
Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992;79:543-53.
Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 19999;341:1051-62.
Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med 1985,103.620-5.
Harris NL, Jaffe ES, Diebold J, et al. WHO classification of neoplastic diseases of the hematopoietic and lymphatic tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997;24:17-31.
Fendux P, Preudhomme C, Lai JL, et al. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia. A reporrt on 283 cases. Br J Haematol 1989;73:61.
Wiernik PH, Banks PLC, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79:313-9.
Arlin Z, Case DC Jr, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphoblastic leukemia (ANLL). Leukemia 1990;4:177-83.
Hammerschmidt DE, Wild Crea MT. Anthracyoline-based therapy of de novo acute myeloid leukemia in adults: Failure of first-cycle cytoreduction to predict second-cycle outcome. Am J Hematol 1994;47:172-7.
Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-7.
Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with duanorubicin in patients with previously untreated acute myeloid leukemia. A Southwest Oncology Group Study. Blood 1996;88:2841-51.
Wolff SN, Herzig RH, Fay JW, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long-term follow-up and results. J Clin Oncol 19897:1260-7.
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med - 1994;331:893-903.
Ho AD, Lipp T, Ehninger G, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia-An active and well-tolerated regimen. J Clin Oncol 1988;6:213-7.
Kantarjian H. New developments in the treatment of acute myeloid leukemia: Focus on topotecan. Semin Hematol 1999;36:16-25.
Sievus EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD 33-positive acute myeloid leukemia in first remission. J Clin Oncol 2001;19:3244-54.
List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporin as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993;11:1652-60.
Greinix HT, Reiter E, Keil F, et al. Long-term leukemia-free survival and mortality inmpatients with refractory or relapsed acute leukemia giving marrow transplants from sibling and unrelated donors. Bone Marrow Transplant 1998;21:673.
Larson RA, Kondo K, Vardiman JW, et al. Evidence for a 15;17 translocation in every patinet with acute promyelocytic leukemia. Am J Med 1984;76:827-41.
O'Donnell MR. Acute leukemias in Cancer Management: A Multidisciplinary Approach. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds). Medical, Surgical & Radiation Oncology. New York: PRR Melville 2001:641-62.
Fennaux P, Chomienne C, Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001;38:13-25.
Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001;98:266-71.
Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo controlled phase III study of granulocytemacrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E 1490). Blood 1995;86:457-62.
Abraham J, Monahan BP. The acute leukemias in Bethesda Handbook of Clinical Oncology. In: Abraham J, Allegra CJ (eds). Philadelphia: Lippincott Williams & Wilkins, 2001:271-85.
Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123-31.
Faderl S, KantarjianHM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia and Lymphoma 2000;36:263-73
Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 19998;339:605-15.
Hoelzer D, Thiel E, Loffler H, et al. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 1984;64:38-47.
ASCO. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-Based Clinical Practice Guidelines. J Clin Oncol 1996;14:1957-60.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
